Personalis to Post Q2 2020 Earnings of ($0.32) Per Share, Oppenheimer Forecasts (NASDAQ:PSNL)

Personalis (NASDAQ:PSNL) – Analysts at Oppenheimer upped their Q2 2020 earnings per share estimates for shares of Personalis in a research note issued to investors on Wednesday, June 24th. Oppenheimer analyst K. Degeeter now anticipates that the company will post earnings of ($0.32) per share for the quarter, up from their previous estimate of ($0.34). Oppenheimer currently has a “Buy” rating and a $24.00 target price on the stock. Oppenheimer also issued estimates for Personalis’ FY2020 earnings at ($1.30) EPS.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The business had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $16.80 million. Personalis had a negative net margin of 40.60% and a negative return on equity of 26.28%.

PSNL has been the topic of several other research reports. ValuEngine upgraded shares of Personalis from a “hold” rating to a “buy” rating in a report on Friday, March 13th. Morgan Stanley raised their price target on shares of Personalis from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Zacks Investment Research lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Friday. Finally, BidaskClub lowered shares of Personalis from a “strong-buy” rating to a “buy” rating in a report on Friday, May 29th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.20.

NASDAQ PSNL opened at $12.74 on Monday. Personalis has a one year low of $4.27 and a one year high of $27.59. The company’s 50 day moving average price is $12.34 and its 200 day moving average price is $10.15. The firm has a market capitalization of $403.99 million and a price-to-earnings ratio of -7.91.

Hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. grew its position in shares of Personalis by 110.9% during the fourth quarter. Victory Capital Management Inc. now owns 3,043 shares of the company’s stock worth $33,000 after buying an additional 1,600 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Personalis by 432.5% during the first quarter. BNP Paribas Arbitrage SA now owns 5,511 shares of the company’s stock worth $44,000 after buying an additional 4,476 shares in the last quarter. Deutsche Bank AG grew its position in shares of Personalis by 95.5% during the first quarter. Deutsche Bank AG now owns 6,081 shares of the company’s stock worth $49,000 after buying an additional 2,971 shares in the last quarter. Barclays PLC grew its position in shares of Personalis by 105.7% during the fourth quarter. Barclays PLC now owns 9,031 shares of the company’s stock worth $98,000 after buying an additional 4,640 shares in the last quarter. Finally, Parametric Portfolio Associates LLC acquired a new stake in shares of Personalis during the first quarter worth approximately $87,000. 60.92% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Lightspeed Venture Partners Se acquired 77,797 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were bought at an average price of $12.98 per share, for a total transaction of $1,009,805.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 8.20% of the company’s stock.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers.

Featured Story: Market Indexes

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.